S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners named Berkshire Hathaway Inc. (NYSE:BRK) as his final trade ahead of its quarterly earnings report on Saturday.

On April 25, UBS analyst Brian Meredith maintained a Buy rating for Berkshire Hathaway and raised the price target from $557 to $606.

Stephen L. Weiss of Short Hills Capital Partners picked Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as his final trade.

Lending support to his choice, Cantor Fitzgerald analyst Carter Gould, on April 22, initiated coverage of Vertex Pharmaceuticals with an Overweight rating and announced a price target of $535.

Don't forget to check out our premarket coverage here

Karen Firestone of Aureus Asset Management said S&P Global Inc. (NYSE:SPGI) reported a great quarter.

S&P Global reported quarterly adjusted earnings per share of $4.37 on Tuesday, beating the analyst consensus estimate of $4.19 per share. Quarterly sales of $3.78 billion (up 8% year over year) outpaced the street view of $3.70 billion. Revenue from subscription products increased 7%.

Joseph M. Terranova of Virtus Investment Partners said he likes CME Group Inc. (NASDAQ:CME).

On the earnings front, CME Group posted first-quarter adjusted earnings of $2.80 per share on April 23, beating market estimates of $2.79 per share. The company's quarterly sales came in at $1.60 billion versus expectations of $1.64 billion.

Price Action:

• Berkshire Hathaway shares fell 0.3% to close at $533.25 on Wednesday.
• Vertex Pharmaceuticals gained 1.2% to close at $509.50 during Wednesday's session.
• S&P Global gained 1.7% to close at $500.05 on Wednesday.
• CME Group shares climbed 1.7% to settle at $277.08 during the session.

Check This Out:

• Top 2 Materials Stocks That May Fall Off A Cliff This Quarter

Photo: Shutterstock